THIRD AMENDED AND RESTATED RESEARCH AND DEVELOPMENT COLLABORATION AGREEMENT BETWEEN THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH AND ATARA BIOTHERAPEUTICS, INC.Research and Development Collaboration Agreement • November 9th, 2020 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This Third Amended and Restated Research and Development Collaboration Agreement (“Third Restated Agreement”), entered into on August 26, 2020 (“Execution Date”), and effective as of the Execution Date, is made by and between Atara Biotherapeutics, Inc., having its principal offices at 611 Gateway Blvd #900, South San Francisco, CA 94080, (“Atara”), and the Council of the Queensland Institute of Medical Research, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”). Each of Atara and Institute are referred to in this Agreement as a “Party”, and collectively as the “Parties”
THIRD AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT between THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH and ATARA BIOTHERAPEUTICS, INC.Exclusive License Agreement • November 9th, 2020 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This THIRD AMENDED AND RESTATED EXCLUSIVE LICENSE AGREEMENT (“Third Restated Agreement”) is entered into on August 26, 2020 (“Execution Date”), and effective as of the Execution Date, by and between the COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH, a not-for-profit Institute organized and existing under the laws of the State of Queensland having its principal offices at 300 Herston Rd, Herston QLD 4006, Australia (“Institute”), and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation located at 611 Gateway Blvd #900, South San Francisco, CA 94080 (“Licensee”). Each of Licensee and Institute are referred to in this Agreement as a “Party” and together, the “Parties”.
FIRST AMENDMENT TO LEASELease • November 9th, 2020 • Atara Biotherapeutics, Inc. • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO LEASE (this “First Amendment”) is made as of October 21, 2020, by and between 611 GATEWAY CENTER LP, a Delaware limited partnership (“Landlord”), and ATARA BIOTHERAPEUTICS, INC., a Delaware corporation (“Tenant”).
